Search

• GSK’s Shingrix new prefilled syringe presentation accepted for review by European Medicines Agency

  Media

  Over 25 million people in Europe have received GSK’s shingles vaccine since 2018.

  https://www.gsk.com/en-gb/media/press-releases/gsk-s-shingrix-new-prefilled-syringe-presentation-accepted-for-review-by-european-medicines-agency/

  First published: 27 January 2025

• GSK plc announces major three-part transaction with Novartis to drive sustainable sales growth, improve long-term earnings and deliver increasing returns to shareholders

  Media

  GSK announces a major conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses

  https://www.gsk.com/en-gb/media/press-releases/gsk-plc-announces-major-three-part-transaction-with-novartis-to-drive-sustainable-sales-growth-improve-long-term-earnings-and-deliver-increasing-returns-to-shareholders/

  First published: 22 April 2014

• ViiV Healthcare to progress collaboration with Janssen to develop the first long-acting, two drug injectable regimen for treatment of HIV-1 infection

  Media

  ViiV Healthcare, Pfizer Inc. and Shionogi Limited with Janssen for cabotegravir and rilpivirine for the treatment of HIV-1 infection.

  https://www.gsk.com/en-gb/media/press-releases/viiv-healthcare-to-progress-collaboration-with-janssen-to-develop-the-first-long-acting-two-drug-injectable-regimen-for-treatment-of-hiv-1-infection/

  First published: 07 January 2016

• GSK presents post-hoc analysis of Anoro® Ellipta® data assessing markers of COPD deterioration compared to tiotropium or placebo using a novel composite endpoint

  Media

  GSK and THRX today announced data presented by GSK at the European Respiratory Society (ERS) International Congress (poster PA1001)

  https://www.gsk.com/en-gb/media/press-releases/gsk-presents-post-hoc-analysis-of-anoro-ellipta-data-assessing-markers-of-copd-deterioration-compared-to-tiotropium-or-placebo-using-a-novel-composite-endpoint/

  First published: 27 September 2015

• GSK and Merck to study immunotherapy combination as potential cancer treatment

  Media

  Phase I human study to evaluate GSK’s OX40 agonist GSK3174998 as monotherapy and in combination with Merck’s anti-PD-1 therapy, Keytruda®

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-merck-to-study-immunotherapy-combination-as-potential-cancer-treatment/

  First published: 03 November 2015

• GSK receives European marketing authorisation for Nucala® (mepolizumab) in 31 countries

  Media

  GSK announced that EMA has granted marketing authorisation for Nucala® as an add-on treatment for severe refractory eosinophilic asthma

  https://www.gsk.com/en-gb/media/press-releases/gsk-receives-european-marketing-authorisation-for-nucala-mepolizumab-in-31-countries/

  First published: 02 December 2015

• GSK and Theravance announce positive data from two studies evaluating the efficacy and safety of Incruse™ Ellipta® when added to Relvar®/Breo® Ellipta® in patients with COPD

  Media

  GSK and THRX today announced positive results from two phase III studies.

  https://www.gsk.com/en-gb/media/press-releases/gsk-and-theravance-announce-positive-data-from-two-studies-evaluating-the-efficacy-and-safety-of-incruse-ellipta-when-added-to-relvar-breo-ellipta-in-patients-with-copd/

  First published: 11 June 2014

• GSK gains accelerated FDA approval for combination use of Mekinist® (trametinib) and Tafinlar® (dabrafenib)

  Media

  GSK announced today that the FDA has approved Mekinist® (trametinib) for use with Tafinlar® (dabrafenib) for the treatment melanoma

  https://www.gsk.com/en-gb/media/press-releases/gsk-gains-accelerated-fda-approval-for-combination-use-of-mekinist-trametinib-and-tafinlar-dabrafenib/

  First published: 09 January 2014

• GSK data presented at ERS demonstrate potential of blood eosinophil levels to help inform COPD treatment decisions

  Media

  GSK presented data at ERS Congress showing blood eosinophil levels may help predict patients with COPD when receiving an ICS regimen.

  https://www.gsk.com/en-gb/media/press-releases/gsk-data-presented-at-ers-demonstrate-potential-of-blood-eosinophil-levels-to-help-inform-copd-treatment-decisions/

  First published: 08 September 2014

• GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business

  Media

  GSK reaches agreement with Novartis to acquire full ownership of Consumer Healthcare Business

  https://www.gsk.com/en-gb/media/press-releases/gsk-reaches-agreement-with-novartis-to-acquire-full-ownership-of-consumer-healthcare-business/

  First published: 27 March 2018